[{"address1": "345 Park Avenue South", "address2": "6th Floor", "city": "New York", "state": "NY", "zip": "10010", "country": "United States", "phone": "212 547 9879", "website": "https://www.lexeotx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.", "fullTimeEmployees": 72, "companyOfficers": [{"maxAge": 1, "name": "Mr. R. Nolan Townsend", "age": 43, "title": "CEO & Director", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 3741748, "exercisedValue": 0, "unexercisedValue": 1392030}, {"maxAge": 1, "name": "Dr. Eric  Adler M.D.", "age": 50, "title": "Chief Medical Officer & Head of Research", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 2705659, "exercisedValue": 0, "unexercisedValue": 112845}, {"maxAge": 1, "name": "Mr. Jordan M. Baumhardt Ph.D.", "title": "Vice President of Corporate Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sandi See Tai M.D.", "age": 53, "title": "Chief Development Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leslie  DiRisio", "title": "Senior Vice President of Development Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  McHenry", "title": "VP & Corporate Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.71, "open": 4.71, "dayLow": 4.585, "dayHigh": 5.55, "regularMarketPreviousClose": 4.71, "regularMarketOpen": 4.71, "regularMarketDayLow": 4.585, "regularMarketDayHigh": 5.55, "payoutRatio": 0.0, "forwardPE": -1.6750902, "volume": 1235704, "regularMarketVolume": 1235704, "averageVolume": 819130, "averageVolume10days": 816080, "averageDailyVolume10Day": 816080, "bid": 3.9, "ask": 5.93, "bidSize": 2, "askSize": 2, "marketCap": 154034080, "fiftyTwoWeekLow": 1.45, "fiftyTwoWeekHigh": 19.5, "fiftyDayAverage": 3.0921, "twoHundredDayAverage": 7.15715, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 42440068, "profitMargins": 0.0, "floatShares": 19862095, "sharesOutstanding": 33197000, "sharesShort": 2939149, "sharesShortPriorMonth": 2215452, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.0885, "heldPercentInsiders": 0.01255, "heldPercentInstitutions": 1.11449, "shortRatio": 2.25, "shortPercentOfFloat": 0.099, "impliedSharesOutstanding": 33197000, "bookValue": 3.533, "priceToBook": 1.3133314, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -98333000, "trailingEps": -3.09, "forwardEps": -2.77, "enterpriseToEbitda": -0.404, "52WeekChange": -0.64875096, "SandP52WeekChange": 0.09765589, "quoteType": "EQUITY", "currentPrice": 4.64, "targetHighPrice": 28.0, "targetLowPrice": 16.0, "targetMeanPrice": 21.14286, "targetMedianPrice": 21.0, "recommendationKey": "none", "numberOfAnalystOpinions": 7, "totalCash": 121518000, "totalCashPerShare": 3.661, "ebitda": -105137000, "totalDebt": 9924000, "quickRatio": 5.319, "currentRatio": 5.52, "debtToEquity": 8.494, "returnOnAssets": -0.46106, "returnOnEquity": -0.85366994, "grossProfits": -74091000, "freeCashflow": -48427376, "operatingCashflow": -81151000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "LXEO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -1.4862032, "regularMarketPrice": 4.64, "corporateActions": [], "postMarketTime": 1746229936, "regularMarketTime": 1746216001, "shortName": "Lexeo Therapeutics, Inc.", "marketState": "CLOSED", "exchange": "NGM", "messageBoardId": "finmb_625814286", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "longName": "Lexeo Therapeutics, Inc.", "postMarketChangePercent": 4.52586, "postMarketPrice": 4.85, "postMarketChange": 0.21, "regularMarketChange": -0.07000017, "regularMarketDayRange": "4.585 - 5.55", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 819130, "fiftyTwoWeekLowChange": 3.1899998, "fiftyTwoWeekLowChangePercent": 2.1999998, "fiftyTwoWeekRange": "1.45 - 19.5", "fiftyTwoWeekHighChange": -14.860001, "fiftyTwoWeekHighChangePercent": -0.7620513, "fiftyTwoWeekChangePercent": -64.8751, "earningsTimestamp": 1742819400, "earningsTimestampStart": 1746793800, "earningsTimestampEnd": 1748003400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.09, "epsForward": -2.77, "epsCurrentYear": -3.084, "priceEpsCurrentYear": -1.5045395, "fiftyDayAverageChange": 1.5479, "fiftyDayAverageChangePercent": 0.5005983, "twoHundredDayAverageChange": -2.51715, "twoHundredDayAverageChangePercent": -0.35169727, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2023-11-03", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1699018200000, "displayName": "Lexeo Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-03"}]